Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free ADXN Stock Alerts

Addex Therapeutics (ADXN) Competitors

Addex Therapeutics logo
$6.84 +0.99 (+16.81%)
Closing price 06/8/2026 03:43 PM Eastern
Extended Trading
$6.78 -0.06 (-0.88%)
As of 04:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ADXN vs. ABVC, NNVC, VIRI, ALGS, and LSTA

Should you buy Addex Therapeutics stock or one of its competitors? MarketBeat compares Addex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Addex Therapeutics include ABVC BioPharma (ABVC), NanoViricides (NNVC), Virios Therapeutics (VIRI), Aligos Therapeutics (ALGS), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.

How does Addex Therapeutics compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

ABVC BioPharma has higher revenue and earnings than Addex Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABVC BioPharma$510K68.31-$7.91M-$0.40N/A
Addex Therapeutics$210K40.09-$8.12M-$5.74N/A

ABVC BioPharma has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.75 beat Addex Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ABVC BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Addex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ABVC BioPharma's return on equity of -62.46% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ABVC BioPharmaN/A -62.46% -39.99%
Addex Therapeutics N/A -105.98%-87.61%

Summary

ABVC BioPharma beats Addex Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Addex Therapeutics compare to NanoViricides?

Addex Therapeutics (NASDAQ:ADXN) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

NanoViricides' return on equity of -87.90% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -105.98% -87.61%
NanoViricides N/A -87.90%-78.69%

Addex Therapeutics has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K40.09-$8.12M-$5.74N/A
NanoViricidesN/AN/A-$8.29M-$0.43N/A

Addex Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NanoViricides
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Addex Therapeutics had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for Addex Therapeutics and 0 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.23 beat Addex Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company Overall Sentiment
Addex Therapeutics Neutral
NanoViricides Neutral

Summary

NanoViricides beats Addex Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Addex Therapeutics compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Addex Therapeutics' return on equity of -105.98% beat Virios Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Virios TherapeuticsN/A -130.33% -115.00%
Addex Therapeutics N/A -105.98%-87.61%

Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Virios Therapeutics has higher earnings, but lower revenue than Addex Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/A-$5.30M-$0.27N/A
Addex Therapeutics$210K40.09-$8.12M-$5.74N/A

In the previous week, Addex Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Addex Therapeutics and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score.

Company Overall Sentiment
Virios Therapeutics Neutral
Addex Therapeutics Neutral

Summary

Addex Therapeutics beats Virios Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Addex Therapeutics compare to Aligos Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Addex Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

In the previous week, Addex Therapeutics and Addex Therapeutics both had 1 articles in the media. Addex Therapeutics' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Addex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aligos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 676.21%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Addex Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Addex Therapeutics' return on equity of -105.98% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -105.98% -87.61%
Aligos Therapeutics -1,919.68%-139.47%-90.88%

Addex Therapeutics has higher earnings, but lower revenue than Aligos Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K40.09-$8.12M-$5.74N/A
Aligos Therapeutics$2.19M14.02-$24.19M-$8.69N/A

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aligos Therapeutics beats Addex Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Addex Therapeutics compare to Lisata Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Lisata Therapeutics' return on equity of -103.54% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -105.98% -87.61%
Lisata Therapeutics N/A -103.54%-83.08%

Addex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Addex Therapeutics has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K40.09-$8.12M-$5.74N/A
Lisata Therapeutics$170K186.41-$16.59M-$1.86N/A

Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 331.03%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 9.6% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Addex Therapeutics had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 1 mentions for Addex Therapeutics and 0 mentions for Lisata Therapeutics. Addex Therapeutics' average media sentiment score of 0.00 equaled Lisata Therapeutics'average media sentiment score.

Company Overall Sentiment
Addex Therapeutics Neutral
Lisata Therapeutics Neutral

Summary

Addex Therapeutics beats Lisata Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADXN vs. The Competition

Export
MetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.22M$2.96B$6.48B$11.99B
Dividend YieldN/A1.70%2.67%5.58%
P/E Ratio-1.1917.6823.6723.74
Price / Sales40.09418.29527.02119.88
Price / CashN/A56.1726.9937.25
Price / Book1.473.8310.446.78
Net Income-$8.12M$75.85M$3.57B$337.51M
7 Day Performance6.54%-2.00%0.26%-2.34%
1 Month Performance0.38%-5.85%3.24%1.88%
1 Year Performance-30.76%14.03%22.22%25.55%

Addex Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADXN
Addex Therapeutics
0.1387 of 5 stars		$6.85
+16.8%		N/A-33.1%$7.22M$210KN/A30
ABVC
ABVC BioPharma
0.7766 of 5 stars		$1.30
+3.6%		N/A-13.0%$33.67M$510KN/A30
NNVC
NanoViricides
0.5109 of 5 stars		$1.54
-3.1%		N/A-7.1%$33.32MN/AN/A20
VIRI
Virios Therapeutics
N/A$1.67
-1.8%		N/A-69.3%$32.16MN/AN/A5
ALGS
Aligos Therapeutics
3.1138 of 5 stars		$5.21
-0.9%		$38.50
+639.7%		-31.1%$32.13M$2.19MN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel